Literature DB >> 2550502

Properties of IgG subclasses to human cytomegalovirus.

G Gilljam1, B Wahren.   

Abstract

The IgG subclass of antiviral antibodies to human cytomegalovirus (CMV) is mainly of IgG1 type. Most CMV seropositive sera also have virus-specific IgG3, but of a lower titre as measured by enzyme-linked immunosorbent assay (ELISA). We studied the reactivity pattern of these two IgG subclasses to CMV structural polypeptides in order to define how virus-specific IgG1 and IgG3 contribute to the neutralization of CMV. Neutralization of CMV was performed with CMV IgG1 and IgG3 separated from CMV seropositive human sera on a protein A Sepharose gel. Both IgG1 and IgG3 have a neutralizing capacity. IgG3 had a 10-fold better neutralizing effect than IgG1 when related to the ELISA titre. In order to analyse the specific reactivities, CMV Towne virion polypeptides were separated by electrophoresis and transferred to nitrocellulose. Using mouse monoclonals to human IgG1 and IgG3 in combination with a biotin-streptavidin system, the reactivities of the subclasses were examined. IgG1 and IgG3 appeared to react with the same structural polypeptides. The strongest IgG1 reactivities were obtained with CMV polypeptides of apparent molecular weights of 145, 80, 64, 56, 52 and 27.5 kDa. The CMV IgG3 reactivity was restricted compared to IgG1, the strongest and most frequent reactivities occurring to polypeptides of 145 and 80 kDa.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2550502     DOI: 10.1016/0166-0934(89)90028-1

Source DB:  PubMed          Journal:  J Virol Methods        ISSN: 0166-0934            Impact factor:   2.014


  8 in total

1.  IgG subclass-specific antibodies to human cytomegalovirus (HCMV)-induced early antigens.

Authors:  A Hamann; H W Doerr
Journal:  Med Microbiol Immunol       Date:  1991       Impact factor: 3.402

2.  Tick-borne encephalitis virus-neutralizing antibodies in different immunoglobulin preparations.

Authors:  Philip O Rabel; Christina B Planitzer; Maria R Farcet; Thomas R Kreil
Journal:  Clin Vaccine Immunol       Date:  2012-02-29

3.  Analytical issues possibly affecting the performance of commercial human cytomegalovirus IgG avidity assays.

Authors:  M Berth; L Grangeot-Keros; F Heskia; J-M Dugua; C Vauloup-Fellous
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2014-04-30       Impact factor: 3.267

4.  Early immune responses accompanying human asymptomatic Ebola infections.

Authors:  E M Leroy; S Baize; P Debre; J Lansoud-Soukate; E Mavoungou
Journal:  Clin Exp Immunol       Date:  2001-06       Impact factor: 4.330

5.  Characterization of human monoclonal antibodies directed against the pp65-kD matrix antigen of human cytomegalovirus.

Authors:  M Ohlin; V A Sundqvist; G Gilljam; U Rudén; F O Gombert; B Wahren; C A Borrebaeck
Journal:  Clin Exp Immunol       Date:  1991-06       Impact factor: 4.330

6.  Predominance of IgG1 and IgG4 subclasses of anti-neutrophil cytoplasmic autoantibodies (ANCA) in patients with Wegener's granulomatosis and clinically related disorders.

Authors:  E Brouwer; J W Tervaert; G Horst; M G Huitema; M van der Giessen; P C Limburg; C G Kallenberg
Journal:  Clin Exp Immunol       Date:  1991-03       Impact factor: 4.330

Review 7.  Humoral immune response to human cytomegalovirus infection: diagnostic potential of immunoglobulin class and IgG subclass antibody response to human cytomegalovirus early and late antigens.

Authors:  B Weber; W Braun; J Cinatl; H W Doerr
Journal:  Clin Investig       Date:  1993-04

8.  Fine specificity of the human immune response to the major neutralization epitopes expressed on cytomegalovirus gp58/116 (gB), as determined with human monoclonal antibodies.

Authors:  M Ohlin; V A Sundqvist; M Mach; B Wahren; C A Borrebaeck
Journal:  J Virol       Date:  1993-02       Impact factor: 5.103

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.